Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

By E. Senkus, S. Kyriakides, S. Ohno, F. Penault-Llorca, P. Poortmans, E. Rutgers, S. Zackrisson, F. Cardoso. Annals of Oncology, 2015

1,699 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/4fb6d1b8be72dbca28669370cbfb02d8b4c5922b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Masakazu Toi
2. S. Tolaney

Citations in the corpus

• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (2020, background): “Standard treatment varies depending on risk of recurrence but includes combinations of surgery, radiotherapy, adjuvant/ neoadjuvant chemotherapy, and endocrine therapy (ET).(3,4) Adjuvant ET (aromatase inhibitors [AIs] and/or antiestrogens with or without ovarian suppression) is standard treatment o”
• Translating RNA sequencing into clinical diagnostics: opportunities and challenges (2016, result): “For example, in breast cancer, recent clinical guidelines support the use of multigene mRNA-based prognostic assays to assist in treatment decisions in conjunction with clinicopathological factors 10, 11 .”